Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Endogenous Molecules as Neuroprotective Entities for the Treatment of Ischemic Stroke
FY 2013-14
Summary
Stroke is an ever-increasing problem in the aging Canadian population. It is the third leading cause of death, associated with highly prevalent risk factors such as high blood pressure, diabetes, and obesity. Although strokes are typically physically debilitating, current treatment is limited, with emphasis on prevention through management of risk factors (Heart and Stroke Foundation, 2012). There is a pressing need for the development of a therapeutic approach that limits neuronal injury in ischemic stroke patients, where ischemia refers to decreased blood supply arising from an occluded artery.
A diversity of neurotoxic factors are released during an ischemic assault that can result in brain damage (Lee, Zipfel, and Choi 1999). An important group of neurotoxic mediators are divalent metal cations. The goal of this research is to develop a method to mitigate the highly toxic influxes of these divalent metal cations, thus limiting neuronal death during an ischemic stroke.
The objective of my research is to design, synthesize, and evaluate new chemical entities that are able to cross the blood brain barrier (BBB), chelate neurotoxic divalent cations, and either “tie them up” or preferably, transport them out of the brain entirely. As a starting point, I will use endogenous compounds as initial design platforms (i.e. is there an endogenous anti-stroke compound and can it be used as a design platform?). Histidine is one such endogenous molecule that is known to chelate divalent metal cations (Nair et al. 2010). Further exploring the ability of histidine and histidine-related analogues to chelate divalent metal cations associated with neurotoxicity during stroke is necessary to determine the biological applicability of this proposed therapy.
Once the chelation ability of histidine and the synthesized analogues is investigated, the results of those studies will be used as a basis for the rational design of new chemical entities useful in the treatment of stroke. Utilizing computer-based methods will allow studies on the effectiveness of these new entities to chelate divalent metal cations. After the chemical synthesis of these NCEs, testing for chelation ability, neuroprotective properties, and toxicity will be conducted. Ideally, a molecule will arise with superior neuroprotective properties that can be further pushed through the phases of drug design.
It is imperative for the Health Sciences field and the general Canadian population to invest in research towards the treatment of ischemic stroke. The wide-reaching scope of this neurodegenerative disease underlines the importance of this proposed project. Research utilizing both chemical and computational techniques represents a viable way to contribute to an understanding that may lead to or help others in the Health Sciences field develop a viable treatment for ischemic stroke.
References:
Heart and Stroke Foundation (2012). “Stroke.” Retrieved October 9, 2013, from Heart and Stroke Foundation of Canada: Heart Disease, Stroke, and Healthy Living: www.heartandstroke.ca.
J.-M. Lee, G.J. Zipfel, & D.W. Choi (1999). “The Changing Landscape of Ischaemic Brain Injury Mechanisms.” Nature, 399 (6738): 7–14.
N.G. Nair, G. Perry, M.A. Smith, and V.P. Reddy (2010). “NMR Studies of Zinc, Copper, and Iron Binding to Histidine, the Principal Metal Ion Complexing Site of Amyloid-Beta Peptide.” Journal of Alzheimer’s Disease, 20 (1): 57–66.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311947
Name
Purcell Mary I
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Endogenous Molecules as Neuroprotective Entities for the Treatment of Ischemic Stroke
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brain Infraction; Chelation; Divalent Metal Cations; Ischemia; Medicinal Chemistry; Molecular Modelling; Neurodegenerative Disease; Spectroscopy; Synthetic Organic Chemistry; Zinc
Abstract
Stroke is an ever-increasing problem in the aging Canadian population. It is the third leading cause of death, associated with highly prevalent risk factors such as high blood pressure, diabetes, and obesity. Although strokes are typically physically debilitating, current treatment is limited, with emphasis on prevention through management of risk factors (Heart and Stroke Foundation, 2012). There is a pressing need for the development of a therapeutic approach that limits neuronal injury in ischemic stroke patients, where ischemia refers to decreased blood supply arising from an occluded artery.
A diversity of neurotoxic factors are released during an ischemic assault that can result in brain damage (Lee, Zipfel, and Choi 1999). An important group of neurotoxic mediators are divalent metal cations. The goal of this research is to develop a method to mitigate the highly toxic influxes of these divalent metal cations, thus limiting neuronal death during an ischemic stroke.
The objective of my research is to design, synthesize, and evaluate new chemical entities that are able to cross the blood brain barrier (BBB), chelate neurotoxic divalent cations, and either “tie them up” or preferably, transport them out of the brain entirely. As a starting point, I will use endogenous compounds as initial design platforms (i.e. is there an endogenous anti-stroke compound and can it be used as a design platform?). Histidine is one such endogenous molecule that is known to chelate divalent metal cations (Nair et al. 2010). Further exploring the ability of histidine and histidine-related analogues to chelate divalent metal cations associated with neurotoxicity during stroke is necessary to determine the biological applicability of this proposed therapy.
Once the chelation ability of histidine and the synthesized analogues is investigated, the results of those studies will be used as a basis for the rational design of new chemical entities useful in the treatment of stroke. Utilizing computer-based methods will allow studies on the effectiveness of these new entities to chelate divalent metal cations. After the chemical synthesis of these NCEs, testing for chelation ability, neuroprotective properties, and toxicity will be conducted. Ideally, a molecule will arise with superior neuroprotective properties that can be further pushed through the phases of drug design.
It is imperative for the Health Sciences field and the general Canadian population to invest in research towards the treatment of ischemic stroke. The wide-reaching scope of this neurodegenerative disease underlines the importance of this proposed project. Research utilizing both chemical and computational techniques represents a viable way to contribute to an understanding that may lead to or help others in the Health Sciences field develop a viable treatment for ischemic stroke.
References:
Heart and Stroke Foundation (2012). “Stroke.” Retrieved October 9, 2013, from Heart and Stroke Foundation of Canada: Heart Disease, Stroke, and Healthy Living: www.heartandstroke.ca.
J.-M. Lee, G.J. Zipfel, & D.W. Choi (1999). “The Changing Landscape of Ischaemic Brain Injury Mechanisms.” Nature, 399 (6738): 7–14.
N.G. Nair, G. Perry, M.A. Smith, and V.P. Reddy (2010). “NMR Studies of Zinc, Copper, and Iron Binding to Histidine, the Principal Metal Ion Complexing Site of Amyloid-Beta Peptide.” Journal of Alzheimer’s Disease, 20 (1): 57–66.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Purcell, Mary I
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~